Home » Stocks » SNSE

Sensei Biotherapeutics, Inc. (SNSE)

Stock Price: $14.50 USD -1.24 (-7.88%)
Updated Mar 4, 2021 4:00 PM EST - Market closed
Market Cap 481.46M
Revenue (ttm) n/a
Net Income (ttm) -21.67M
Shares Out 29.56M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 4
Last Price $14.50
Previous Close $15.74
Change ($) -1.24
Change (%) -7.88%
Day's Open 15.89
Day's Range 13.60 - 16.00
Day's Volume 266,926
52-Week Range 13.60 - 26.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 3 days ago

If the insiders are buying, other investors should at least pay attention. These seven stocks are ones to keep an eye on here.

Other stocks mentioned: CERN, DD, HSIC, INCY, MTD, NUS
GlobeNewsWire - 3 weeks ago

BOSTON and ROCKVILLE, Md., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation th...

GlobeNewsWire - 1 month ago

BOSTON and ROCKVILLE, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation th...

Business Wire - 1 month ago

BOSTON & ROCKVILLE, Md.--Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announc...

SEC - 1 month ago

Sensei Biotherapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

NASDAQ - 1 month ago

Sensei Biotherapeutics, a Phase 2 biotech developing bacteriophage-based therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

BostInno - 1 month ago

Sensei Biotherapeutics, a clinical-stage cancer immunotherapy company that opened a Boston research and development hub last year, has attracted high-profile investors for its $30 million Seri...

About SNSE

Sensei Biotherapeutics, a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further en... [Read more...]

Industry
Biotechnology
IPO Date
Feb 4, 2021
CEO
John Celebi
Employees
24
Stock Exchange
NASDAQ
Ticker Symbol
SNSE
Full Company Profile

Financial Performance

Financial Statements